MBRX
Price:
$2.4
Market Cap:
$6.83M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma mul...[Read more]
Industry
Biotechnology
IPO Date
2016-06-02
Stock Exchange
NASDAQ
Ticker
MBRX
According to Moleculin Biotech, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.20. This represents a change of -66.77% compared to the average of -0.60 of the last 4 quarters.
The mean historical PE Ratio of Moleculin Biotech, Inc. over the last ten years is -274.98. The current -0.20 PE Ratio has changed -92.73% with respect to the historical average. Over the past ten years (40 quarters), MBRX's PE Ratio was at its highest in in the March 2001 quarter at 0. The PE Ratio was at its lowest in in the March 2016 quarter at -1288.87.
Average
-274.98
Median
-5.64
Minimum
-2288.82
Maximum
-0.85
Discovering the peaks and valleys of Moleculin Biotech, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 79.68%
Maximum Annual PE Ratio = -0.85
Minimum Annual Increase = -96.26%
Minimum Annual PE Ratio = -2288.82
Year | PE Ratio | Change |
---|---|---|
2023 | -0.85 | -22.73% |
2022 | -1.11 | -80.39% |
2021 | -5.64 | 79.68% |
2020 | -3.14 | 11.27% |
2019 | -2.82 | -91.71% |
2018 | -34.03 | -35.60% |
2017 | -52.84 | -38.27% |
2016 | -85.60 | -96.26% |
The current PE Ratio of Moleculin Biotech, Inc. (MBRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.53
5-year avg
-2.71
10-year avg
-274.98
Moleculin Biotech, Inc.’s PE Ratio is greater than Catalyst Biosciences, Inc. (-0.44), greater than Pulmatrix, Inc. (-0.67), less than Cyclacel Pharmaceuticals, Inc. (-0.11), greater than Akari Therapeutics, Plc (-1.55), greater than Onconova Therapeutics, Inc. (-1.15), less than Bio-Path Holdings, Inc. (-0.14), greater than AN2 Therapeutics, Inc. (-0.47), greater than Miromatrix Medical Inc. (-3.41), greater than Inhibikase Therapeutics, Inc. (-0.55), greater than PMV Pharmaceuticals, Inc. (-1.58), greater than Anebulo Pharmaceuticals, Inc. (-4.99), less than Diffusion Pharmaceuticals Inc. (-0.00), greater than Capricor Therapeutics, Inc. (-4.65), greater than NextCure, Inc. (-0.65), less than Panbela Therapeutics, Inc. (-0.06), greater than Virax Biolabs Group Limited (-1.34), less than Allarity Therapeutics, Inc. (-0.19), less than ContraFect Corporation (-0.11), greater than Avenue Therapeutics, Inc. (-0.31),
Company | PE Ratio | Market cap |
---|---|---|
-0.44 | $19.42M | |
-0.67 | $7.30M | |
-0.11 | $2.09M | |
-1.55 | $35.02M | |
-1.15 | $20.90M | |
-0.14 | $2.51M | |
-0.47 | $30.44M | |
-3.41 | $92.95M | |
-0.55 | $10.00M | |
-1.58 | $77.28M | |
-4.99 | $46.68M | |
-0.00 | $8.98M | |
-4.65 | $132.76M | |
-0.65 | $39.73M | |
-0.06 | $1.75M | |
-1.34 | $15.24M | |
-0.19 | $7.01M | |
-0.11 | $1.72M | |
-0.31 | $4.05M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moleculin Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Moleculin Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Moleculin Biotech, Inc.'s PE Ratio?
How is the PE Ratio calculated for Moleculin Biotech, Inc. (MBRX)?
What is the highest PE Ratio for Moleculin Biotech, Inc. (MBRX)?
What is the 3-year average PE Ratio for Moleculin Biotech, Inc. (MBRX)?
What is the 5-year average PE Ratio for Moleculin Biotech, Inc. (MBRX)?
How does the current PE Ratio for Moleculin Biotech, Inc. (MBRX) compare to its historical average?